Dr Thomas Karmark Dreyer speaks to ecancer about reducing the number of flexible cystoscopies in patients undergoing follow-up for non-muscle invasive bladder cancer with either flexible cystoscopy or the urinary biomarker test bladder cancer monitor.

This randomised clinical trial named DaBlaCa-15 aimed to determine the number of flexible cystoscopies required for patients undergoing surveillance for high-grade NMIBC.

The trial compared patients undergoing surveillance with flexible cystoscopies versus those undergoing surveillance mainly with the urinary biomarker test Xpert Bladder Cancer Monitor.

The study found that the Xpert Bladder Cancer Monitor test resulted in a reduction in the number of follow-up cystoscopies during surveillance. This study is ongoing, and the author discusses what the next steps will be.